Available from: Lin J, Pearson SA, Greenfield JR, Park KH, Havard A, Brieger D et al (2023) Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in Australia in the era of increased evidence of their cardiovascular benefits (20142022)
Lixisenatide is a daily GLP-1RA developed by Zealand Pharma, which prolongs its half-life through structure-inducing probe technology based on exendin-4/exenatide
Early trial data suggest retatrutide could lead to greater average weight loss than tirzepatide, but its long-term safety, side effects, and real-world tolerability are still being studied
That means connecting them with licensed providers who truly understand their needs, nutritional guidance that's actually personalized, and a community that has their back
Three years later, Byetta, the first GLP-1 agonist, was approved by the FDA
PMID: 33631448